Could it be the buy of the century? NNVC on the AMEX
Nanovircides, Inc. (NNVC) is a functional biotechnology SEC reporting company with shares traded on the AMEX.
NNVC is recognized on a commercial basis by the FDA and European counterparts. They are acknowledged as a legitimate and innovative company for the technical prowess and therapeutic nanotechnology drug development achievements. While they currently have no marketed products, nor have they earnings, they are in late stage development of revolutionary anti-viral therapeutics using polymeric nanomicelles both as their delivery and active anti-viral platform.
The basics of the NNVC ant-viral approach can be reviewed in Chapter 7 of the CRC publication Bionanotechnology II (ISBN -10: 143980463X).
Using their proprietary approach, and working within the rigid pharmaceutical industry protocols, NNVC has perform both in-vitro and in-vivo testing, as is required prior to human phase studies. In these studies, a high degree efficacy was seen and documented by a wide range of entities, across a range of viral types. This is rather uncommon in typical developmental stage companies. Many focus on a singular type as a target.
NNVC is however more interested in ultimately having a platform that can be quickly tuned and adjusted to target nearly any viral type, even those that might be highly novel or of recent or immediate surfacing threats. This has extended NNVCs testing phase years as they have worked with many researchers and agencies around the world to assess their approach across a wide spectrum of viral types.
Not only have they been proven highly effective, the fact that the course of their studies having being done at a wide range of facilities provides additional confidence that efficacies are indeed very real and not unique to a particular viral type or testing agency protocols, methods and unique handlings.
The following can be referenced as a sample of NNVCs achievements. (H5N1 & Rabies at the National Institute of Hygiene and Epidemiology in Hanoi, Ebola studies with the United States Army Institute of Infectious Diseases, Epidemic Kerato-Conjunctivitis EKC, anti-Herpes clinical study with THEVAC and Herpes Simplex Virus HSV with Dr. Rosenthal at NEOMED, anti-HIV therapeutics testing with the University of California in addition to KARD Scientific, Dengue Fever tests with Dr. Eva Harris at the University of California, Berkeley, et.al)
Both in-vitro and in-vivo testing has reported excellent efficacy against the viral types targeted, with no apparent or significant toxicity issues observed.
After a successful pre-IND meeting with the FDA, NNVC is now currently in the process of completing the work needed to proceed to first human phase testing.
NNVC is also upgrading their facilities to improve production capability. This will not only ensure sufficient quantities of the therapeutics for FDA stage gate testing, but also for a wide range of researchers highly interested in testing the efficacy against viral types of specific world concern.
With the high level of efficacy and lack of toxicity shown to date in specialized animal models, and the expanding interest from foreign investigators, there is a reasonable possibility that first human testing may occur outside of the United States.
The FDA and the corresponding European agencies were also impressed enough to grant the NNVC Denque Fever anti-viral an orphan drug designation.
NNVC has redirected their efforts from time-to-time over their short history to take advantage of opportunities presented to them to evaluate efficacy against particular viral types of immediate or contemporary concern. While this has slowed their progress to human testing on a single viral type, it has served their overall goal well, which is to bring to the world an anti-viral platform to help eradicate nearly any virus at any time, of whatever type, wherever it might break out.
Their ultimate goal is not to have an anti-flu therapeutic, but a universal anti-any viral therapeutic that can be adjusted and applied in a very rapid time span.
Well respected doctors and researchers in their field have been impressed by the efficacy tests they participated in. Reference Dr. Eva Harris at the University of California, Berkeley Berekely, Dr. Rosenthal at NEOMED, as well as others mentioned above and/or available in the literature.
The Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, was asked why he invested a total of $7M ($7,000,000.00 USD) in NNVC during the 2013 calendar year. His answer was, “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
It would be naïve of anyone, including the writer, to assume NNVC has been perfect in its march towards its lofty goals and/or that clear skies lie ahead.
Like all companies, NNVC has been presented with its own set of corporate, technical, business and legal issues. However, if one studies the actual progress toward demonstrating the efficacy of NNVC anti-viral therapeutics across the very wide range of viral types tested so far, it is astounding how much they have achieved for each unit dollar of investment over the last 9 years. In doing so, from a developmental company standpoint and from an industry comparative and historical perspective, NNVC has demonstrated good stewardship of funding by achieving excellent efficacy results for the total invested dollar value to date.
It is important for all investors to do their own due diligence and avoid the tendencies to follow or blindly assume accuracy and legitimacy of positive or negative commentary, including this by the writer. Also critical is to understand one’s risk level and to especially beware of misinformation. Recognize that not all misinformation is intentional, while other cases are indeed malicious and/or manipulative in nature.
The writer currently maintains a small equity position in NNVC common stock and as such could be suspected of bias. While not in the medical or pharmaceutical field, a background in science and engineering, including chemical process R&D experience, has been of immense help to the writer in recognizing true technical merit in areas investigated over the last 30+ years.
All said and considered, it is the writer’s opinion NNVC is BUY in the speculative biotech equity category.
Wishing All the Best of Good Buys!
HS
AI
